These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 20975605

  • 1. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
    Kłosowska-Wardęga A, Hasumi Y, Åhgren A, Heldin CH, Hellberg C.
    Melanoma Res; 2011 Feb; 21(1):57-65. PubMed ID: 20975605
    [Abstract] [Full Text] [Related]

  • 2. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C.
    Int J Cancer; 2007 Dec 15; 121(12):2606-14. PubMed ID: 17691110
    [Abstract] [Full Text] [Related]

  • 3. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T.
    Cancer; 2005 May 01; 103(9):1800-9. PubMed ID: 15786421
    [Abstract] [Full Text] [Related]

  • 4. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ.
    J Natl Cancer Inst; 2003 Mar 19; 95(6):458-70. PubMed ID: 12644539
    [Abstract] [Full Text] [Related]

  • 5. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
    Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE, Salvado AJ, Friedman HS.
    Cancer; 2009 May 15; 115(10):2188-98. PubMed ID: 19248046
    [Abstract] [Full Text] [Related]

  • 6. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 7. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
    Yamaguchi SI, Ueki A, Sugihara E, Onishi N, Yaguchi T, Kawakami Y, Horiuchi K, Morioka H, Matsumoto M, Nakamura M, Muto A, Toyama Y, Saya H, Shimizu T.
    Cancer Sci; 2015 Jul 01; 106(7):875-82. PubMed ID: 25940371
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M.
    J Invest Dermatol; 2004 Feb 01; 122(2):400-5. PubMed ID: 15009722
    [Abstract] [Full Text] [Related]

  • 12. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA, Laug WE, Sausville EA, Avramis VI.
    Cancer Chemother Pharmacol; 2003 Oct 01; 52(4):307-18. PubMed ID: 12827297
    [Abstract] [Full Text] [Related]

  • 13. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H, Tan X, Dong Y, Giese A, Chou TC, Rainov N, Yang B.
    Basic Clin Pharmacol Toxicol; 2009 Mar 01; 104(3):241-52. PubMed ID: 19159435
    [Abstract] [Full Text] [Related]

  • 14. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
    Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON.
    Proc Natl Acad Sci U S A; 2004 Dec 14; 101(50):17456-61. PubMed ID: 15505216
    [Abstract] [Full Text] [Related]

  • 15. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
    Palmberg E, Johnsen JI, Paulsson J, Gleissman H, Wickström M, Edgren M, Ostman A, Kogner P, Lindskog M.
    Int J Cancer; 2009 Mar 01; 124(5):1227-34. PubMed ID: 19058199
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
    Spigel D, Jones S, Hainsworth J, Infante J, Greco FA, Thompson D, Doss H, Burris H.
    Cancer Invest; 2011 May 01; 29(4):308-12. PubMed ID: 21469980
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.